On 29 November 2023, OncoSil Medical Ltd, a medical device company focusing on localised treatments for patients with locally advanced pancreatic cancer (LAPC), held its Annual General Meeting (AGM) in Melbourne, Australia.
AGM Presentation Highlights
- Corporate Overview: OncoSil Medical, listed on ASX under the ticker $OSL since 15 August 2005, holds a market capitalization of $15.8 million with 1975.8 million shares issued. The share price stands fluctuates between a 52-week high of $0.041 and a low of $0.008​​
- OncoSil Device and Market Position: The OncoSil device, a commercial breakthrough in targeted radiotherapy for pancreatic cancer, has gained significant traction. It is approved for sale in 34 countries, with a large global addressable market, including a yearly global population of approximately 130,000 patients​​.
- Significant Accomplishments: OncoSil Medical has achieved key milestones, including CE Marking, US FDA breakthrough device designation, and successful completion of the PanCO Study, demonstrating the device’s safety and efficacy​​. 33% of patients treated with OncoSil became eligible for surgical resection, and 57% saw at least a 50% reduction in tumour volume​​.
- Commercialisation Progress: The early-stage commercialisation of the OncoSil device has already begun, with a focus on expanding the addressable market and securing innovation funding in Germany.
OncoSil Medical has made notable progress over the past year, marked by significant regulatory achievements and early commercial success. The company remains focused on expanding the market reach of its innovative OncoSil device and securing necessary funding to support further growth and development.
